Roots Analysis

AUGUST 15, 2023

Biomanufacturing utilizing cell free systems is an emerging area of research that enables the synthesis of different biomolecules, such as cytotoxic proteins, fusion proteins, post translationally modified proteins, antibodies, enzymes, vaccines and other complex proteins, without the use of living cells.

Protein 52

Protein In-Vitro Production Reagent 52

The Pharma Data

AUGUST 19, 2021

The test evaluates a panel of MMR proteins in tumours to provide important treatment information to clinicians. Defects in the MMR machinery have been attributed to mutations in the MMR proteins. MMR is a naturally occurring mechanism that scans our DNA, correcting errors that cause disease. Source link: [link].

FDA Approval 52

FDA Approval DNA Reagent Protein 52

pharmaphorum

FEBRUARY 3, 2021

This can be partly attributed to the reagents and delivery modalities that were available at the time of the trial start in 2016, leading to low editing efficiency at the target loci. However, the number of CAR-T cells with all four genes correctly targeted was low.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

Roots Analysis

FEBRUARY 13, 2023

Messenger ribonucleic acid (mRNA) is a single-stranded molecule, which carries coding sequence and plays a prominent role in protein synthesis. It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH), a leading provider of proteins, antibodies and cytokines today announced that its Woburn, Massachusetts site received ISO 13485:2016 certification for Medical Device and Quality Management Systems. MINNEAPOLIS , Oct. ” About Bio-Techne Corporation (NASDAQ: TECH).

Manufacturing 40

Manufacturing Reagent Gene Therapy Protein 40

Roots Analysis

AUGUST 28, 2022

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. In fact, platform integration agreements account for 18% of the total deals inked in this domain, since 2016.

Genome 52

Genome Genomics RNA Genome Project 52

The Pharma Data

JANUARY 24, 2021

He is an inventor on numerous patents and has published papers in the fields of protein structure and engineering, immunology, and oncology. Bond led monoclonal and bi-specific antibody discovery and engineering programs targeting cancer stem cell antigens at OncoMed Pharmaceuticals. Dr. Bond received a Ph.D.

Engineer 52

Engineer Gene Editing Genome Genomics 52

Roots Analysis

OCTOBER 16, 2023

Once isolated, molecular clones can be used to generate multiple copies of DNA for the analysis of gene sequences and / or to express proteins obtained for the study or utilization of protein function. These clones can be manipulated and mutated in vitro to alter the expression and function of a protein.

DNA 40

DNA Gene Protein In-Vitro 40

The Pharma Data

MARCH 16, 2022

TIB Molbiol offers a broad range of VirSNiP variant test kits for the detection of key spike protein mutations. The company launched eight RUO VirSNiP test kits for use on LightCycler® and cobas z 480 analyzers, for the detection of key spike protein mutations present in the novel B.1.1.529 1.1.529 Omicron SARS-CoV-2 variant.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

The Pharma Data

OCTOBER 19, 2020

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. It allows the test to be used for people without any symptoms or suspicion of COVID-19, supporting widespread population testing. Please read more here. .

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

XTalks

APRIL 22, 2022

Flow cytometry is an analytical technique that is used to detect the presence of cell surface markers as well as intracellular proteins using antibodies in individual cells suspended in a buffer solution, which pass through a laser beam one at a time ( Figure 1 ). What is Flow Cytometry? What is a Receptor Occupancy Assay?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

FDA Law Blog

MARCH 16, 2023

This device is indicated for the following use: for the rapid, qualitative detection of SARS-CoV-2 nucleocapsid protein antigens directly in anterior nasal swab specimens from individuals with signs and symptoms of upper respiratory infection (i.e., symptomatic) when testing is started within 6 days of symptom onset.

Marketing 40

Marketing In-Vitro Regulation Reagent 40

The Pharma Data

OCTOBER 14, 2020

The highly potent and selective payload series represents a powerful new class within ADC development with novel protein alkylating cytotoxicity. Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing In-Vivo 52

Roots Analysis

JANUARY 27, 2025

Protein therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. Considering their vast potential, close to 50% of the top selling drugs in 2023 were protein therapeutics.

Protein 40

Protein Reagent Marketing Gene 40

XTalks

JANUARY 6, 2025

RNA-Based Therapeutics RNA molecules have emerged as promising therapeutic agents due to their ability to precisely target undruggable proteins or molecules, often with minimal side effects. The global next-generation biomanufacturing market is projected to grow at a CAGR of 14.85 percent from 2021 to 2031, reaching an estimated value of $85.2

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111

XTalks

MARCH 11, 2025

Additionally, manufacturers often use proprietary codon optimization schemes, meaning that even mRNA constructs for the same protein may differ significantly at the nucleotide level. The result was a prepackaged, off-the-shelf reagent kit that provided reliable quantification for a wide variety of influenza mRNA vaccine constructs.

Vaccination 64

Vaccination Vaccine Development Manufacturing 64